Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vitamin D3 Not Recommended as Psoriasis Treatment

J Dermatolog Treat; ePub 2017 Aug 29; Jarrett, et al

Vitamin D3 supplementation (100,000 IU per month) is not recommended as a treatment for mild psoriasis, according to a recent study. Participants with psoriasis in a large, randomized, controlled trial examining the effect of vitamin D3 supplementation in adults aged 50-84 years, participated in a psoriasis sub-study over 12 months. The primary outcome was the Psoriasis Area and Severity Index (PASI) and secondary outcomes were Physicians Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Psoriasis Disability Index (PDI). 23 subjects were allocated to vitamin D and 42 to placebo; mean (SD) baseline 25-hydroxyvitamin D was 65.7 (25.7) nmol/L. Researchers found:

  • There was no significant difference at baseline between the 2 groups.
  • There were no significant differences between the groups in all of the psoriasis outcome measures.
  • Mean scores at 12 months for the placebo vs vitamin D groups: PASI 2.2 [1.4, 3.0] vs 2.1 [1.0, 3.2]; PGA 1.4 [1.1, 1.7] vs 1.5 [1.1, 1.9]; PDI 2.1 [0.9, 3.2] vs 1.9 [0.4, 3.4]; and DLQI 2.5 [1.4, 3.6] vs 2.0 [0.5, 3.4].


Jarrett P, Camargo Jr CA, Coomarasamy C, Scragg R. A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis. [Published online ahead of print August 29, 2017]. J Dermatolog Treat. doi:10.1080/09546634.2017.1373735.


Although topical therapy with vitamin D analogues are indicated for the treatment of psoriasis, this study demonstrated that supplementation with Vitamin D3 did not exhibit significant improvement in PASI scores, PGA, and DLQI in patients with mild psoriasis. The limitation in this study was that enrolled patients had mild psoriasis and changes in lower PASI scores from baseline are not as sensitive compared to higher baseline PASI scores. Several decades ago, vitamin D3 supplementation was used to treat psoriasis. However extremely high doses were utilized and there were severe adverse events, such as tetany and hypercalcemia. —Paul S. Yamauchi, MD, PhD

This Week's Must Reads

Link Between AD and Autoimmune Disorders, J Am Acad Dermatol; ePub 2018 Oct 1; Narla, et al

Predictors of Mucosal Melanoma Survival, J Am Acad Dermatol; ePub 2018 Oct 5; Altieri, et al

Prevalence of Acne Vulgaris Among Patients with HS, J Am Acad Dermatol; ePub 2018 Oct 1; Wertenteil, et al

Skin Disease Epidemiology in a Diverse Population, J Drugs Dermatol; 2018 Oct; Gaulding, et al

Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8

Must Reads in Psoriasis

Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8

Latent TB Prevalent in Patients with Psoriasis, J Dermatolog Treat; 2018 Nov; Lee, Amin, et al

Understanding Scope of Cutaneous Pain in Psoriasis, J Dermatolog Treat; ePub 2018 Sep 26; Pithadia, et al

Ixekizumab Proves Effective in Psoriasis Treatment, J Clin Pharmacol; 2018 Nov; Chigutsa, et al

QOL Impaired in Young Adults with Psoriasis, J Dermatolog Treat; ePub 2018 Sep 7; Bronckers, et al